Dear LUGPA Colleagues,
At the 2016 LUGPA Annual Meeting, the APM Task Force announced our formal collaboration between LUGPA and Integra Connect to develop advanced alternative payment models (APMs). LUGPA will collaborate with Integra Connect and industry sponsors to develop multiple urology-specific APMs. As we transition from a fee-for-service reimbursement model to one of value-based care, LUGPA is dedicated to providing leadership to assist our members with the development and validation of urology-specific APMs.
Currently, there are no eligible APM options for urology, but the Centers for Medicare and Medicaid Services (CMS) recognize the need for specialty-specific APMs and have created a process by which stakeholders can develop and submit specific APM models for its review and approval. For a LUGPA member practice to benefit from an APM, providers need integrated clinical and financial systems which can monitor not only treatment pathway adherence and quality metrics but also patient outcomes and practice costs.
After an extensive search, the LUGPA board selected Integra Connect as its partner to develop urology-specific APMs. Integra Connect has deep experience with population health management and payer initiatives which will assist LUGPA with the MACRA transition to value-based care.
Initially, we will develop two APM projects with LUGPA practice involvement:
- Prostate Cancer Biopsy Taking Risk on Sepsis; and
- Positive Biopsy/Localized Prostate Cancer.
LUGPA will be contacting groups that have expressed an interest in participating at our annual meeting a few weeks ago. We will keep the entire LUGPA community apprised of our efforts.
Neal D. Shore, MD, FACS
Gary M. Kirsh, MD
Chair, LUGPA APM Task Force